News
News Release
Cyclomedical Applications Group, LLC
Welcomes Another Associate
Contact: James F. Lamb, Ph.D.
+1-865-670-9021
jlamb@cyclomedical.com
KNOXVILLE, Tennessee,
2004 April 15—Cyclomedical Applications Group is pleased to welcome another new Associate to its group of experts who can offer positron emission tomography (PET) services and capabilities to clients.
Mr. Scott Minor has accumulated 14 years of experience in the manufacturing, installation, service, training and routine operation of PET isotope cyclotrons. His experience covers the cyclotron systems of both CTI and GE Medical Systems. He has established Accelerator Consulting Services, Inc. to provide routine and emergency service, parts and technical support for independent owners/operators of PET cyclotron systems, worldwide.
He is also experienced in the installation and troubleshooting of FDG production modules, as well as techniques for improving FDG production yields and target material utilization, while reducing operator exposure. His radiochemical expertise can also be applied to routine PET compound manufacturing and quality assurance operations.
Dr. James Lamb, President of Cyclomed, announced, “We are pleased to add Scott to our expanding group of experts, further enhancing the service and support that we can offer our PET accelerator clients.”
Cyclomedical Applications Group is an organization of experienced radiopharmaceutical experts serving the radiopharmaceutical industry, especially owners and operators of medical cyclotrons dedicated to the production of positron emitting radioisotopes. It works primarily with facilities producing and distributing F-18 FDG–the most widely used positron-emitting radiopharmaceutical in PET scanning.
Consulting services offered by the company range from short-term consultation to longer-term retainer arrangements and assistance with regulatory agencies as well as cyclotron operation and FDG production problems. Contract management services range from full responsibility for a cyclotron/FDG production facility to a monitoring posture in support of an in-place management team.
Cyclomed’s goal is to provide a full range of support expertise including FDG market research and development, facility financing, facility planning and operation, licensing and safety, and FDA regulatory issues. The company currently has operational responsibility for several cyclotron/FDG facilities and is providing cyclotron consultation services to a number of cyclotron operating companies. For more information, see the Cyclomed web site at www.cyclomedical.com.